Top Tech Companies (764)
Don't see your company?
Create a company profile
Industry leader, specializing in conduct of Investigational Vaccine Trials. We have 6 Clinical Sites around the United States - Austin, Ft. Worth, San Angelo, New Orleans, Sacramento and San Francisco. Benchmark's superior team of motivated and focused investigators offers clinical trials experience in a wide range of therapeutic areas. Our knowledgeable investigators enthusiastically embrace clinical research and the opportunities that new therapies bring to the marketplace and patients. Dedication and experience aside, our investigators are also highly trained in GCP and FDA regulations.
Earli mission is to make cancer a benign experience. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology *forces* cancer cells to make a synthetic, non-human biomarker using gene therapy approaches. It's called a Synthetic Biopsy. It can then localize the cancer in a PET scanner. Earli has been funded by Andreessen Horowitz's Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coast’s prime biotech hub in South San Francisco.
Wake Research is an integrated network of premier investigational sites working closely with and meeting the needs of the global biopharmaceutical, biotechnology, medical device, pharmaceutical industry, and clinical research organizations. Wake Research has its proprietary patient database of more than 2 million potential clinical trial participants—men and women, children and adults, across all ethnicities—for all kinds of adaptive and other types of trial designs. Conducting studies since 1984, we have a combined subject database of more than 2 million, and we’re still growing. As of today, our board-certified physicians have completed more than 7,000 successful clinical trials. Clinical trials at our site are always completed on time and with accuracy; we consistently exceed sponsor expectations for integrity, subject enrollment, human protection, and expeditious delivery of accurate evaluable data. Our approach is uncompromising – each study conducted at our site is carefully planned and executed according to regulations with superior quality.
PLx Pharma develops and commercializes non-steroidal anti-inflammatory drugs for prescription and over-the-counter markets.
Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
A location based software platform for healthcare applications.
Cisplatin and other platinum compounds are essential chemotherapeutic components for many pediatric malignancies. Unfortunately, platinum-based therapies can cause ototoxicity in many patients, leaving many survivors of childhood cancer with permanent and irreversible hearing loss. Permanent hearing loss, even minimal, acquired at a young age has a devastating impact on development, education, and socialization and a lifelong negative impact on Quality of Life. There are no currently approved treatments for the prevention of platinum-induced hearing loss. At Fennec Pharmaceuticals, we are dedicated to the development of our investigational agent, PEDMARK™, for the prevention of ototoxicity in children, and we hope that this will enable more children to retain their hearing. In honor of our namesake, the fennec fox, we strive to embody adaptability and resourcefulness in everything we do. Please see www.fennecpharma.com for more information.
Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases.
Award-winning clinical research organization (CRO) that delivers high-quality clinical trials through strong relationships with specialization in oncology, neurology and rare diseases.
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in clinical and commercial manufacturing production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking, and support services from its Oklahoma City state-of-the-art facilities.
Amplyx focuses on developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems
Dompé is an Italian bio-pharmaceutical company that focuses on innovation, where a long tradition in the field of personal wellness goes hand in hand with a commitment to research and development to meet hitherto unsatisfied therapeutic needs. Established in 1940 in Milan, Dompé continues to have its headquarters in this city. In Italy, it also has offices in L’Aquila, with an industrial and biotech research hub, and in Naples, where the Company has an R&D division. Dompé also has branches in the United States (Boston and San Francisco), in Albania (Tirana) and China (Shanghai). Primary Care Dompé, with its products offered at over 10,000 pharmacies in Italy, is engaged in the development and distribution of ethical drugs and self-medication, adjuvants, medical devices and cosmetics, and in the fields of vitamin and mineral supplements and personal hygiene. The therapeutic areas include cardiovascular, gastrointestinal, paediatrics, neurology, urology, ophthalmic, stomatology and respiratory. Dompé currently markets 50 million medication packages in roughly 40 countries around the world. Biotech and rare diseases The Biotech unit is a manifestation of Dompé commitment to meeting unsatisfied patient needs all around the world. The Biotech Unit focuses specifically on the rare diseases field, such as ophthalmology, for instance, an area in which the company has developed and marketed the first ophthalmic product based on rhNGF (the molecule discovered by Nobel Prize winner Rita Levi Montalcini) for patients suffering from neurotrophic keratitis. For more information on Dompé visit www.dompe.com To explore career opportunities at Dompé visit http://www.dompe.com/Careers-en/
Generian has developed an innovative approach to uncover first-in-class, gain-of-function drugs that activate key cellular networks.
Aesthetics technology firm that develops and globally commercializes novel cosmetic products
NextSource Biotechnology is a biotechnology and pharmaceutical company located in Miami.
Pernix Therapeutics develops and markets branded and generic pharmaceutical products for the pediatric market.
Avolynt is a clinical stage pharmaceutical company developing novel therapeutics for the treatment of rare and metabolic disease.
At Flipt, we are determined to disrupt the status quo and invent a new kind of pharmacy benefit management. Our mission is to give plan sponsors an easy-to-implement benefits solution and plan members an easy-to-use platform that lowers costs by promoting price transparency and consumer choice while better aligning interests throughout the healthcare system.
The longest running rare-disease and specialty pharma agency.
Biolytx Pharmaceuticals developing a drug focused on promoting wound healing and killing antibiotic resistant bacteria.
